• Senseonics’ Eversence continuous glucose monitoring product provides the company with a tremendous opportunity, but developing this market doesn’t come cheap.
• In order to accelerate acceptance, Senseonics is investing in a new program, but in the short term this is adding to costs.
• In our view, the company will still have substantial cash needs next year, which keeps us on the sidelines here.

Source: Senseonics Will Still Need To Go Back To The Markets – Senseonics Holdings, Inc. (NYSEMKT:SENS) | Seeking Alpha